Drug Protects Heart Patients from Attacks

Research Updates

A study by our Cell Therapeutics Group has revealed that an anti-inflammatory medication used to treat gout can also improve heart health in people who have suffered a heart attack or other major heart event.

The discovery, published in the prestigious Journal of the American Heart Association, paves the way for a new treatment regime that could protect thousands of British heart patients from future attacks that will kill or further damage the heart.

"Excitingly, we've been able to prove that this low-cost and widely available drug is both safe and profoundly effective in reducing local cardiac inflammation," says Dr Sanjay Patel, group leader of the Cell Therapeutics Group at the HRI. "If we're able to prove its success in larger studies, we'll have a brand new therapy that will considerably brighten the outlook for people who suffer heart attacks."

Dr Patel and his team investigated new treatments for acute coronary syndrome, a sudden and life-threatening condition in which the coronary blood vessel is blocked, triggering a heart attack or severe chest pain associated with unstable angina.

The condition, most commonly caused by atherosclerosis or thickened arteries, is often diagnosed on the operating table following a major heart event. Patients are closely managed in hospital but new treatments are still desperately needed to reduce the risk of future attacks.

Dr Patel hypothised that the drug colchicine, with its anti-inflammatory qualities, could combat the inflammation that plays a strong role in cardiovascular disease. HRI collaborated with researchers from the University of Cambridge (UK), Catholic University School of Medicinein (Chile), the Paris-Cardiovascular Research Centre (France), Royal Prince Alfred Hospital and the University of Sydney (Australia), to test out the hypothesis in 83 patients.

Two doses of the drug were given the day before a coronary angiogram, a common procedure to investigate the state of a patient's heart vessels. When the angiogram was carried out the researchers tested levels of key inflammatory cytokines, substances that drive inflammation and disease progression.

"Patients with acute coronary syndrome will have higher levels of these cytokines that work to trigger the dangerous inflammation around the heart," Dr Patel explains. "We discovered that colchicine has a striking ability to suppress the release of these cytokines, effectively stopping inflammation in its tracks."

Specifically, researchers saw a rapid and significant drop in levels of interleukin-1 and interleukin-18 within the coronary arteries, as well as a drop in interleukin-6, a key downstream cytokine strongly associated with artery-thickening inflammation.

"This is an exciting finding as IL-6 is precursor to C-reactive protein, or CRP, which is significantly associated with the incidence of future cardiovascular events in patients with atherosclerosis," Dr Patel says.

Exactly how colchicine inhibits the production of inflammatory cytokines is not completely understood but the team believes the drug works by blocking the NLRP3 inflammasome, a protein complex within immune cells responsible for the production of active IL-1 and IL-18.

This is the first time the effects of colchicine on cardiac cytokine release have been studied in humans or animals, making the findings all the more important.

"The next step will be to prove clinical effect through rigorous multi-centre clinical trials,” explains Dr Patel.  "If it works we have a cheap yet potent treatment with very important therapeutic implications for heart patients."

This project was generously funded by the Walter and Eileen Ralston Trust.

Previous
Next

Related news

A sharing of minds

Breakthrough findings on the biological functions and translational importance of plasminogen activation and extracellular proteolysis – key molecules and chemical pathways in a vast number of biological processes – were presented at the recent Plasminogen Activation and Extracellular Proteolysis Gordon Research Seminar.

Read more

Smart new nanoparticle makes good drugs brilliant

Scientists at Heart Research Institute have engineered multifunctional nanoparticles that can effectively work as ‘nanocarriers’, hauling a wide range of molecules including drugs or genetic material, to exactly where it needs to go in the body. These super-charged nanoparticles with truck-like power and GPS-style precision are poised to change the way medication is delivered to sick Australians.

Read more

Meet the team: Dr Miguel Santos

For Dr Miguel Santos, science has always been a path he knew he wanted to follow. “Be curious. Be determined. Don’t be afraid to do things differently and push the boundaries to make great discoveries.”

Read more